Cargando…

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience

Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but their efficacy in ILD progression remains uncertain. Nintedanib, an antifibrotic agent that slows pulmonary function decline, has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boutel, Maria, Boutou, Afroditi, Pitsiou, Georgia, Garyfallos, Alexandros, Dimitroulas, Theodoros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093288/ https://www.ncbi.nlm.nih.gov/pubmed/37046439 http://dx.doi.org/10.3390/diagnostics13071221

Ejemplares similares

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)
por: Jee, Adelle S., et al.
Publicado: (2017)

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
por: Spagnolo, Paolo, et al.
Publicado: (2021)

Vitamin D levels are prognostic factors for connective tissue disease associated interstitial lung disease (CTD-ILD)
por: Gao, Yujuan, et al.
Publicado: (2020)

Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers
por: Cerro Chiang, Giuliana, et al.
Publicado: (2023)

Association of Red Blood Cell Distribution Width Levels with Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
por: Shi, Shenyun, et al.
Publicado: (2021)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
por: Erre, Gian Luca, et al.
Publicado: (2021)

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
por: Yoo, Hongseok, et al.
Publicado: (2020)

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
por: Yoo, Hongseok, et al.
Publicado: (2022)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Minopoulou, Ioanna, et al.
Publicado: (2021)

Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
por: Gagiannis, Daniel, et al.
Publicado: (2020)

Peripheral microangiopathy in precapillary pulmonary hypertension: a nailfold video capillaroscopy prospective study
por: Arvanitaki, Alexandra, et al.
Publicado: (2021)

Study protocol for connective tissue disease-associated interstitial lung disease trial (TEL-CTD-ILD): A randomized controlled trial of a home-based telemonitoring of treatment effects
por: Małysiak-Szpond, Sylwia, et al.
Publicado: (2022)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

ChILD – Children's interstitial lung disease
Publicado: (2018)

Nicotine treatment and smoking cessation in the era of COVID-19 pandemic: an interesting alliance
por: Boutou, Afroditi K., et al.
Publicado: (2020)

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry
por: Raghu, Ganesh, et al.
Publicado: (2016)

Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax
por: Yamakawa, Hideaki, et al.
Publicado: (2021)

SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib
por: Ravanetti, Francesca, et al.
Publicado: (2021)

Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
por: Cottin, Vincent, et al.
Publicado: (2019)

Children’s Interstitial and Diffuse Lung Diseases (ChILD) in 2020
por: Ferraro, Valentina Agnese, et al.
Publicado: (2020)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment
por: Fragoulis, George E, et al.
Publicado: (2019)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

An unusual case of interstitial lung disease: Revisiting peribronchiolar metaplasia interstitial lung disease (PBM‐ILD)
por: Jung, Flora, et al.
Publicado: (2023)

Choosing pharmacotherapy for ILD in patients with connective tissue disease
por: Wu, Zhe, et al.
Publicado: (2021)

Surfactant Metabolism Dysfunction and Childhood Interstitial Lung Disease (chILD)
por: McFetridge, Lynne, et al.
Publicado: (2009)

Endothelial dysfunction in COPD: a systematic review and meta-analysis of studies using different functional assessment methods
por: Theodorakopoulou, Marieta P., et al.
Publicado: (2021)

Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China
por: Xiaohong, Xie, et al.
Publicado: (2021)

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study
por: Rzepka-Wrona, Patrycja, et al.
Publicado: (2022)

Connecting The Dots (CTD 2022)
Publicado: (2022)

Connecting The Dots (CTD 2023)
por: Annovi, Alberto, et al.
Publicado: (2023)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8hrfq11u32cj2m99dfv3elv6v6